ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0240

Mechanisms of Diuretic Resistance and Diuretic Response in the LOT-MDR Mechanistic Randomized Controlled Trial: A Prespecified Analysis

Session Information

  • Pharmacology
    November 08, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Authors

  • Aston, Natalie E., Yale University School of Medicine, Department of Internal Medicine, Section of Cardiology, New Haven, Connecticut, United States
  • Mette, Christopher D., Yale University School of Medicine, Department of Internal Medicine, Section of Cardiology, New Haven, Connecticut, United States
  • Rao, Veena, Yale University School of Medicine, Department of Internal Medicine, Section of Cardiology, New Haven, Connecticut, United States
  • Cox, Zachary L., Yale University School of Medicine, Department of Internal Medicine, Section of Cardiology, New Haven, Connecticut, United States
  • Ivey-Miranda, Juan B., Yale University School of Medicine, Department of Internal Medicine, Section of Cardiology, New Haven, Connecticut, United States
  • Testani, Jeffrey M., Yale University School of Medicine, Department of Internal Medicine, Section of Cardiology, New Haven, Connecticut, United States
Background

The LOT-MDR trial compared diuretic escalation strategies in acute heart failure (AHF) and diuretic resistance (DR). In a prespecified analysis, we hypothesized DR in the loop of Henle (DR-Loop) would respond favorably to loop intensification and DR in the distal nephron (DR-Distal) would respond best to adjuvant thiazide.

Methods

Hospitalized AHF patients (N=100) with DR (<100mmol Na excretion to screening IV loop diuretic) were randomized to 2.5X IV loop diuretic dose intensification or IV chlorothiazide added to the same loop dose. At screening, DR was categorized as DR-Loop, an increase in fractional excretion of lithium (FELi, measuring Na exiting the loop of Henle) below the population median value 4.4%, or DR-Distal (increased FELi above the median).

Results

Loop intensification significantly increased urine loop diuretic delivery [median 203% (IQR 147%, 259%)]. A ceiling effect of loop intensification was not observed for natriuresis nor FELi up to 400mg IV furosemide equivalents. The increase in diuretic delivery and relative increase in FELi did not differ by DR mechanism (p=0.77 and p=0.99 respectively). However, loop intensification paradoxically produced less augmentation in natriuresis (p=0.004) in DR-Loop compared to DR-Distal, due to a larger absolute augmentation of FENa and FELi in DR-Distal. The improvement in natriuresis with adjuvant thiazide was not superior in patients with DR-Distal compared to DR-Loop (p=0.54).

Conclusion

Contrary to the hypotheses, treating DR-Loop with loop diuretic intensification and treating DR-Distal with adjuvant thiazide did not preferentially improve natriuresis. Subtherapeutic diuretic delivery is not the primary mechanism for DR-Loop, and transport through NCC is not the primary compensatory mechanism in DR-Distal.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)